172 related articles for article (PubMed ID: 15073130)
21. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
22. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
24. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms.
Arnal-Estapé A; Tarragona M; Morales M; Guiu M; Nadal C; Massagué J; Gomis RR
Cancer Res; 2010 Dec; 70(23):9927-36. PubMed ID: 21098707
[TBL] [Abstract][Full Text] [Related]
25. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A
Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
27. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
28. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
29. Active signaling by Neu in transgenic mice.
DiGiovanna MP; Lerman MA; Coffey RJ; Muller WJ; Cardiff RD; Stern DF
Oncogene; 1998 Oct; 17(14):1877-84. PubMed ID: 9778054
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
31. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
32. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
33. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
34. Maximizing the response to Herceptin therapy through optimal use and patient selection.
Leyland-Jones B
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S11-7. PubMed ID: 11989522
[TBL] [Abstract][Full Text] [Related]
35. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
36. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
37. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
[TBL] [Abstract][Full Text] [Related]
38. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
[TBL] [Abstract][Full Text] [Related]
39. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis.
Weinstein EJ; Leder P
Cancer Res; 2000 Jul; 60(14):3856-61. PubMed ID: 10919660
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Anisimov VN; Khavinson VK; Provinciali M; Alimova IN; Baturin DA; Popovich IG; Zabezhinski MA; Imyanitov EN; Mancini R; Franceschi C
Int J Cancer; 2002 Sep; 101(1):7-10. PubMed ID: 12209581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
